CN114409654A - Intermediate synthesis method of BTK inhibitor - Google Patents

Intermediate synthesis method of BTK inhibitor Download PDF

Info

Publication number
CN114409654A
CN114409654A CN202111659739.XA CN202111659739A CN114409654A CN 114409654 A CN114409654 A CN 114409654A CN 202111659739 A CN202111659739 A CN 202111659739A CN 114409654 A CN114409654 A CN 114409654A
Authority
CN
China
Prior art keywords
btk inhibitor
reaction
solution
compound
synthesizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111659739.XA
Other languages
Chinese (zh)
Inventor
范敏华
聂良邓
周学来
张震
陈林渺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhui Puli Pharmaceutical Co ltd
Original Assignee
Anhui Puli Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anhui Puli Pharmaceutical Co ltd filed Critical Anhui Puli Pharmaceutical Co ltd
Priority to CN202111659739.XA priority Critical patent/CN114409654A/en
Publication of CN114409654A publication Critical patent/CN114409654A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention provides a synthesis method of an intermediate of a BTK inhibitor, which comprises the following steps: will contain a compound
Figure DDA0003447133750000011
The organic solution reacts with an organic solution of a format reagent isopropyl magnesium chloride lithium chloride to obtain a reaction solution A; reacting the reaction solution A with a compound
Figure DDA0003447133750000012
After the reaction, the organic solution is added into an ammonium chloride solution for quenching, then extraction and layering are carried out, and the organic layer is decompressed and concentrated to obtain an intermediate of the target compound BTK inhibitor. The synthesis method provided by the invention has the advantages of mild reaction conditions, sufficient raw material conversion, high yield of the obtained compound and less impurities.

Description

Intermediate synthesis method of BTK inhibitor
Technical Field
The invention relates to the technical field of organic synthesis, in particular to a method for synthesizing an intermediate of a BTK inhibitor.
Background
As the process advances, the intermediate requirements for BTK inhibitors increase, and the preformulations do not match: under the existing synthesis method for producing the intermediate of the BTK inhibitor, the dangerous material butyl lithium is mainly used as a raw material and needs to be carried out under severe reaction conditions such as ultralow temperature and the like, so that the preparation of the intermediate of the BTK inhibitor is limited.
Because the intermediate compound of the BTK inhibitor in the prior art has poor safety, harsh reaction conditions, low production efficiency and many defects, a compound preparation method which has good safety, mild reaction conditions, high production efficiency and easy operation is needed on the basis. In view of the above, the present application proposes a method for synthesizing an intermediate of a BTK inhibitor.
Disclosure of Invention
The invention aims to provide a method for synthesizing an intermediate of a BTK inhibitor, which has the advantages of good safety, mild reaction conditions, high production efficiency and easiness in operation.
The invention adopts the following technical scheme to solve the technical problems:
a method for synthesizing an intermediate of a BTK inhibitor, comprising the steps of:
(1) will contain a compound
Figure BDA0003447133730000011
The organic solution reacts with an organic solution of a format reagent isopropyl magnesium chloride lithium chloride to obtain a reaction solution A;
(2) reacting the reaction solution A with a compound
Figure BDA0003447133730000021
After the reaction, the organic solution is added into an ammonium chloride solution for quenching, then extraction and layering are carried out, and the organic layer is decompressed and concentrated to obtain an intermediate of the target compound BTK inhibitor.
The specific reaction equation is as follows:
Figure BDA0003447133730000022
further, the solvent used in the organic solution includes tetrahydrofuran.
Further, the reaction temperature in the step (1) is-10-5 ℃, and the reaction time is 1-4 hours.
Further, the reaction temperature in the step (2) is-10-5 ℃, and the reaction time is 2-6 h.
Further, the concentration of the ammonium chloride is 10-30%.
Further, the extract was ethyl acetate.
Furthermore, the internal temperature in the decompression concentration process is less than or equal to 45 ℃, and the vacuum degree is less than or equal to 0.08 Mpa.
The invention has the advantages that:
the invention aims to overcome the defects of poor safety, harsh reaction conditions, low production efficiency and the like in the compound preparation process in the prior art, and provides a compound preparation method which has the advantages of good safety, mild reaction conditions, high production efficiency and easiness in operation. The method avoids using dangerous material butyl lithium, and can obtain yield higher than the original reaction condition without reacting under ultralow temperature. The process has the advantages of mild reaction conditions, full conversion of raw materials, high yield of the obtained compound and less impurities.
Drawings
FIG. 1 is a liquid chromatogram of an intermediate prepared to yield a BTK inhibitor using a prior art synthetic route;
FIG. 2 is a liquid chromatogram of an intermediate of a BTK inhibitor in example 1 of the present invention.
Detailed Description
The invention is further illustrated by the following examples, which are intended to illustrate, but not to limit the invention further.
In the prior art, an organic solution containing a compound I and an organic solution containing butyl lithium react at a temperature of-65 to-80 ℃ to obtain a reaction solution, then the reaction solution reacts with an organic solution containing a compound II at a temperature of-65 to-80 ℃, the reaction solution is added into an ammonium chloride solution for quenching, then a solvent ethyl acetate is used for extraction and delamination, an organic layer is concentrated, and the ethyl acetate is used for pulping and filtering to obtain an intermediate of a target compound BTK inhibitor; the specific reaction equation is as follows:
Figure BDA0003447133730000031
the invention provides another intermediate synthesis method of the BTK inhibitor, which avoids using dangerous material butyl lithium and can obtain yield higher than the original reaction condition without reacting under ultralow temperature.
In the invention, the prior art is improved, and a method for synthesizing an intermediate of a BTK inhibitor is provided, which comprises the following steps:
(1) will contain a compound
Figure BDA0003447133730000032
The organic solution reacts with an organic solution of a format reagent isopropyl magnesium chloride lithium chloride to obtain a reaction solution A;
(2) reacting the reaction solution A with a compound
Figure BDA0003447133730000041
After the reaction, the organic solution is added into an ammonium chloride solution for quenching, then extraction and layering are carried out, and the organic layer is decompressed and concentrated to obtain an intermediate of the target compound BTK inhibitor.
Wherein the solvent used in the organic solution comprises tetrahydrofuran; the reaction temperature in the step (1) is-10-5 ℃, and the reaction time is 1-4 h; the reaction temperature in the step (2) is-10-5 ℃, and the reaction time is 2-6 h; the concentration of the ammonium chloride is 10-30%; the extract liquor is ethyl acetate; the internal temperature in the decompression concentration process is less than or equal to 45 ℃, and the vacuum degree is less than or equal to 0.08 Mpa.
The following specific examples are provided to further illustrate the present invention by way of preferred examples only and are not intended to represent limiting reaction conditions for the synthesis provided by the present invention:
example 1
Example 1 providesA method for synthesizing an intermediate of a BTK inhibitor, comprising the steps of: containing compounds I
Figure BDA0003447133730000042
Reacting the tetrahydrofuran organic solution with a tetrahydrofuran organic solution of a format reagent isopropyl magnesium chloride lithium chloride at 0 ℃ for 1 hour to obtain a reaction solution, and then reacting the reaction solution with a compound II
Figure BDA0003447133730000043
Reacting the tetrahydrofuran organic solution for 2 hours at 0 ℃, adding the tetrahydrofuran organic solution into an ammonium chloride solution with the concentration of 20 percent for quenching, extracting by using a solvent of ethyl acetate, layering, concentrating the organic layer under reduced pressure at the internal temperature of 45 ℃ and the vacuum degree of 0.08Mpa, pulping by using ethyl acetate, and filtering to obtain an intermediate of the target compound BTK inhibitor.
The specific reaction equation is as follows:
Figure BDA0003447133730000051
the product prepared in the prior art was subjected to liquid chromatography analysis tests under the following conditions in table 1:
table 1: purity chromatography method-liquid phase
Figure BDA0003447133730000052
The liquid chromatogram obtained according to the above test conditions is shown in fig. 1 and 2, the data of the liquid chromatogram in fig. 1 corresponds to table 2 below, and the data of the liquid chromatogram in fig. 2 corresponds to table 3 below.
Table 2:
Figure BDA0003447133730000053
Figure BDA0003447133730000061
as can be seen from fig. 1 and table 2: the product peaks at 21.6min, the liquid phase purity is 96.39%, the impurity content is more, and the impurity content exceeds 0.5% in 21.8min and 25.8 min; the quality of the product is poor.
Table 3:
time of liquid phase peak Peak area Peak area ratio Peak height
1 9.729 9237 0.073 693
2 17.626 6005 0.047 1740
3 18.680 1121 0.009 166
4 19.383 2141 0.017 658
5 19.569 1123 0.009 417
6 20.339 1771 0.014 629
7 20.705 4334 0.034 1512
8 21.529 12380697 97.675 3584282
9 21.695 47110 0.372 12588
10 21.794 52927 0.418 16047
11 22.498 4788 0.038 1644
12 22.921 2419 0.019 872
13 22.988 1994 0.009 393
As can be seen from fig. 2 and table 3: the product peaks at 21.6min, the liquid phase purity is 97.67%, and all other impurities are less than 0.5%; meets the quality standard of the product.
Finally, it should be noted that: the above embodiments are only used to illustrate the present invention and do not limit the technical solutions described in the present invention; it will be understood by those skilled in the art that the present invention may be modified and equivalents may be substituted; all such modifications and variations are intended to be included herein within the scope of this disclosure and the present invention and protected by the following claims.

Claims (7)

1. A method for synthesizing an intermediate of a BTK inhibitor is characterized by comprising the following steps:
(1) will contain a compound
Figure FDA0003447133720000011
The organic solution reacts with an organic solution of a format reagent isopropyl magnesium chloride lithium chloride to obtain a reaction solution A;
(2) reacting the reaction solution A with a compound
Figure FDA0003447133720000012
After the reaction, the organic solution is added into an ammonium chloride solution for quenching, then extraction and layering are carried out, and the organic layer is decompressed and concentrated to obtain an intermediate of the target compound BTK inhibitor.
2. A process of synthesizing an intermediate of a BTK inhibitor according to claim 1, wherein the solvent used in the organic solution comprises tetrahydrofuran.
3. The method for synthesizing the intermediate of a BTK inhibitor according to claim 2, wherein the reaction temperature in the step (1) is-10 to 5 ℃ and the reaction time is 1 to 4 hours.
4. The method for synthesizing the intermediate of a BTK inhibitor according to claim 1, wherein the reaction temperature in the step (2) is-10 to 5 ℃ and the reaction time is 2 to 6 hours.
5. A process according to claim 1, wherein the concentration of ammonium chloride is 10-30%.
6. A process of synthesizing an intermediate of a BTK inhibitor according to claim 1, wherein said extract is ethyl acetate.
7. The method for synthesizing the intermediate of a BTK inhibitor according to claim 1, wherein the internal temperature during the vacuum concentration is not more than 45 ℃ and the vacuum degree is not more than 0.08 MPa.
CN202111659739.XA 2021-12-30 2021-12-30 Intermediate synthesis method of BTK inhibitor Pending CN114409654A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111659739.XA CN114409654A (en) 2021-12-30 2021-12-30 Intermediate synthesis method of BTK inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111659739.XA CN114409654A (en) 2021-12-30 2021-12-30 Intermediate synthesis method of BTK inhibitor

Publications (1)

Publication Number Publication Date
CN114409654A true CN114409654A (en) 2022-04-29

Family

ID=81270517

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111659739.XA Pending CN114409654A (en) 2021-12-30 2021-12-30 Intermediate synthesis method of BTK inhibitor

Country Status (1)

Country Link
CN (1) CN114409654A (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0578362A (en) * 1990-01-16 1993-03-30 Takeda Chem Ind Ltd Condensed heterocyclic compound, its production and use, and intermediate therefor
WO2006090261A1 (en) * 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
US20090286783A1 (en) * 2008-05-19 2009-11-19 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US20160257689A1 (en) * 2015-02-27 2016-09-08 Incyte Corporation Salts and processes of preparing a pi3k inhibitor
WO2017111787A1 (en) * 2015-12-23 2017-06-29 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
CN109890821A (en) * 2016-08-24 2019-06-14 艾科尔公司 Amino-pyrrolopyrimidine ketone compound and its application method
CN110759916A (en) * 2014-08-15 2020-02-07 正大天晴药业集团股份有限公司 Pyrrolopyrimidines as TLR7 agonists
WO2020239124A1 (en) * 2019-05-31 2020-12-03 Fochon Pharmaceuticals, Ltd. SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
WO2021202688A1 (en) * 2020-04-02 2021-10-07 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0578362A (en) * 1990-01-16 1993-03-30 Takeda Chem Ind Ltd Condensed heterocyclic compound, its production and use, and intermediate therefor
WO2006090261A1 (en) * 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
US20090111805A1 (en) * 2005-02-24 2009-04-30 Pfizer Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
US20090286783A1 (en) * 2008-05-19 2009-11-19 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
CN110759916A (en) * 2014-08-15 2020-02-07 正大天晴药业集团股份有限公司 Pyrrolopyrimidines as TLR7 agonists
US20160257689A1 (en) * 2015-02-27 2016-09-08 Incyte Corporation Salts and processes of preparing a pi3k inhibitor
WO2017111787A1 (en) * 2015-12-23 2017-06-29 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
CN109890821A (en) * 2016-08-24 2019-06-14 艾科尔公司 Amino-pyrrolopyrimidine ketone compound and its application method
WO2020239124A1 (en) * 2019-05-31 2020-12-03 Fochon Pharmaceuticals, Ltd. SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
WO2021202688A1 (en) * 2020-04-02 2021-10-07 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
刘雨燕 等: "LiCl 促进的多官能团格氏试剂的制备及应用研究进展", 《有机化学》 *
黄淑娟: "新型BTK抑制剂Abivertinib在急性髓细胞白血病中的应用及其作用机制研究", 《中国博士学位论文全文数据库医药卫生科技辑》 *

Similar Documents

Publication Publication Date Title
CN109336831B (en) Method for recovering triazine ring from triazine ring wastewater
US20150094498A1 (en) Processes and systems for the production of propylene glycol from glycerol
CN113429275B (en) Method for reducing production cost of pseudo ionone
CN107935970B (en) Preparation method of high-purity low-water-content 3-methylamine tetrahydrofuran
CN114409654A (en) Intermediate synthesis method of BTK inhibitor
CN111039801A (en) Utilization method of cyclohexane oxidation by-product light oil
CN114835661A (en) Industrial preparation method of a-acetyl-r-butyrolactone
CN107778141B (en) Purification method of 1, 4-butanediol
CN110577491B (en) Method for preparing 2-chloro-5-chloromethyl pyridine
CN110835296B (en) Preparation process of 2,2, 4-trimethyl-3-hydroxypentanoic acid
CN110105341B (en) Recycling process of excessive triazole potassium in propiconazole synthesis
CN114105802A (en) Method for controlling metal ions and chromaticity in preparation process of N-ethylformamide
CN113548952A (en) Preparation method of high-quality pseudo ionone
CN112479938A (en) Preparation method of N-cyclohexyl-2-aminoethanesulfonic acid
CN108147988B (en) Preparation method of lactam compound with high chiral purity
CN112679512A (en) Tributine intermediate and preparation method thereof
CN114213266B (en) Synthesis process of high-purity D-N- (2, 6-xylyl) alanine methyl ester
CN111057017B (en) Method for recovering 3-mercapto-5-methyl-1, 2, 4-triazole from triazine ring cyclization mother liquor
CN114736103B (en) Method for separating propyl guaiacol and propyl syringol from lignin oil
CN115636742B (en) Recrystallization method
CN113387981B (en) Synthesis method of diethyl phosphite
CN112876438B (en) Separation and purification method of high-purity 3-acetamido-5-acetylfuran
CN106947791B (en) Method for synthesizing atazanavir intermediate chlorohydrin by using biological enzyme catalysis
CN117402071A (en) Post-treatment method of aniline-nitrobenzene condensation reducing solution
CN203333539U (en) Separation and recovery device of alcoholysis liquid waste in polyvinyl alcohol production

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination